Webinar: Importance of reliable antibodies in tumor pathology
with focus on gynecological pathology - In this webinar, Dr. Eugenia Kuteeva will discuss the importance of highly validated antibodies for pathology research with particular focus on female genital tract pathology
Online
Abstract:
Immunohistochemistry (IHC) is widely used in modern anatomic pathology both for diagnostic classification of tumors and as companion diagnostic to drug treatment. In female genital tract pathology, the main categories of tumors have some distinctive IHC features, and IHC can be used to establish or confirm diagnosis. It can be particularly important for diagnosis and classification of poorly differentiated neoplasms and metastatic tumors. Highly validated, specific and sensitive primary antibodies are of crucial importance for the IHC studies.
The Human Protein Atlas project (HPA, www.proteinatlas.org) is a large-scale Swedish initiative aiming at mapping the entire human proteome in both normal and tumor tissues using antibody-based approach. Building on the heritage of the HPA, Atlas Antibodies is continuously working on development of novel monoclonal antibodies, the PrecisA Monoclonals™. A great effort is put into careful design and validation of the antibodies, which can be used for studying pathophysiological mechanisms of cancer, as well as diagnostic and prognostic markers in pathology.
You will learn about:
- The general principles of IHC use in pathology
- Importance of stringent antibody validation for obtaining reliable results
- Pathology section of the Human Protein Atlas
- Atlas Antibodies’ novel monoclonal antibodies for female genital tract pathology
- Example of antibody use in gynecological tumor pathology study
Speaker: Dr. Eugenia Kuteeva, Principal Scientist at Atlas Antibodies
She has a solid background in biology and 20 years of experience in histochemical techniques. At Atlas Antibodies, Dr. Kuteeva’s established an immunohistochemistry lab for histology-based validation of antibodies and biomarker studies. Her work is now focusing on development and validation of novel PrecisA Monoclonals ™ antibodies for pathology, neuroscience, cell biology and stem cell research.
When: Thursday, Oct 27 2022 08:00 OR 15.00 CEST
Where: Online (free)
Missed the Webinar?